🔗 Share this article

As the US proceeds with historic revisions to its vaccination guidelines, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning coronavirus vaccinations in the global health crisis and has focused upon possible deaths after COVID-19 vaccination in her brief tenure at the FDA.

Planned Changes to Childhood Vaccine Program

Public health authorities had intended to unveil sweeping changes to the childhood immunization program recently, bringing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of alignment with many the world with insufficient data for public health gain. The announcement has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the event. She was just designated interim head of the FDA’s CDER, the fifth person to lead the center this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the agency – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US in order to be more in line with Denmark's approach, a country with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Høeg has no obvious track record in drug development, approval processes or management, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the CDER, stated Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a major agency. She has no expertise in industry regulation.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who led the center have had.”

CDER has an immense workload at the agency, she emphasized.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office clears a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and every single one need to be managed,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the role, which oversees more than 5,000 employees. “It is a enormous leadership role, if you execute it properly,” she said.

Official Statement and Controversial Programs

When asked about questions about Høeg’s credentials and whether this selection represents greater collaboration among regulatory chiefs on immunizations, a press secretary responded that the “questions are based on inaccurate presumptions”.

“Her resume aligns with the responsibilities of her job,” the representative said, noting the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the agency head's recently launched priority voucher program, a disputed expedited drug-approval program that allegedly concerned her preceding directors. “By what process are these drugs being picked for this expedited pathway? Who takes the choices?” Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards less stringent regulations of all drugs, with the exception of immunizations.”

Documented Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if troubling, past, some experts said. She published a study using non-validated crowd-sourced reports to determine the incidence of myocarditis following COVID-19 vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed altering rules for novel immunizations and discontinuing “non-essential” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has reportedly suggested excluding young men from obtaining Covid vaccines.

“She’s an all-around ideologue who starts off with her beliefs and reverse-engineers to accommodate the evidence in a highly deceptive, dishonest way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of fellow skeptics, {like|